Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Wall Street Thinks These 2 Nasdaq Stocks Could Go Parabolic Soon
11:38am, Thursday, 15'th Sep 2022
NASH is a common disease, but there are no approved treatments for it. These two drug companies have promising candidates in clinical trials.
Viking Therapeutics to Participate at Upcoming Investor Conferences
04:05pm, Tuesday, 06'th Sep 2022
SAN DIEGO , Sept. 6, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic
Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q2 2022 Results - Earnings Call Transcript
07:35pm, Wednesday, 27'th Jul 2022
Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q2 2022 Results Conference Call July 27, 2022 4:30 PM ET Company Participants Stephanie Diaz - Manager of Investor Relations Brian Lian - President and Chief E
Viking Therapeutics to Report Financial Results for Second Quarter 2022 on July 27, 2022
04:02pm, Wednesday, 20'th Jul 2022
Conference Call Scheduled for Wednesday, July 27 at 4:30 p.m. Eastern Time SAN DIEGO , July 20, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceut
Pfizer (PFE) Gets Fast Track Designation for NASH Therapy
05:34pm, Friday, 27'th May 2022 Zacks Investment Research
Pfizer (PFE) obtains Fast Track designation for its investigational combination therapy - ervogastat and clesacostat for the treatment of NASH.
Insiders Buy More Than $50M Of 3 Penny Stocks
12:51pm, Wednesday, 04'th May 2022 Benzinga
Gold futures traded lower on Wednesday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence or concern around the company
Viking Therapeutics (VKTX) Q1 2022 Earnings Call Transcript
04:30am, Thursday, 28'th Apr 2022 The Motley Fool
VKTX earnings call for the period ending March 31, 2022.
Viking Therapeutics' (VKTX) CEO Brian Lian on Q1 2022 Results - Earnings Call
10:49pm, Wednesday, 27'th Apr 2022
Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q1 2022 Earnings Conference Call April 27, 2022 4:30 PM ET Company Participants Stephanie Diaz – Manager-Investor Relations Brian Lian – President and Chie
Intercept (ICPT) Outperforms Industry in 3 Months: What Lies Ahead?
03:36pm, Friday, 22'nd Apr 2022 Zacks Investment Research
Intercept (ICPT) lead drug Ocaliva holds ground amid challenges. A positive readout from the NASH studies will be a good boost for the stock in the year ahead.
Viking Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
04:05pm, Wednesday, 06'th Apr 2022
SAN DIEGO , April 6, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic an
Intercept (ICPT) Q4 Earnings & Sales Beat, Ocaliva in Focus
04:03pm, Thursday, 03'rd Mar 2022 Zacks Investment Research
Intercept (ICPT) posts a narrower loss in the fourth quarter and sales beat estimates.
3 Biotech Stocks That Are too Cheap to Ignore
08:36pm, Thursday, 10'th Feb 2022 The Motley Fool
Our Motley Fool roundtable likes Intercept Pharma, Viking Therapeutics, and Vir Bio.
Viking Therapeutics rises 8% following Q4 results
04:44pm, Thursday, 10'th Feb 2022 Seeking Alpha
Viking Therapeutics <> stock shot up Feb. 10 following its Q4 results on Feb
3 Biotech Stocks That Are too Cheap to Ignore
03:36pm, Thursday, 10'th Feb 2022
Our Motley Fool roundtable likes Intercept Pharma, Viking Therapeutics, and Vir Bio.
Thinking about buying stock in Dermata Therapeutics, Ironnet, Preferred Apartment Communities, Mattel, or Viking Therapeutics?
01:50pm, Thursday, 10'th Feb 2022 Benzinga
NEW YORK , Feb. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DRMA, IRNT, APTS, MAT, and VKTX. Full story available on Benzinga.com
